Rapamycin slows aging in mice
What this study shows
Answered a crucial objection: does rapamycin really slow AGING, or just prevent the cancers that kill mice? By showing slower age-related change across many tissues (heart, liver, tendon, activity), it argued for genuine slowing of aging. Honestly reported harms too - more cataracts and testicular degeneration - making it a balanced landmark, not hype.
At a glance
| Evidence type | A Animal model Marked A because it is an animal intervention or observation study measuring an organismal outcome (model: Genetically heterogeneous mice); the code names the system studied -- animal work can be rigorous and still not be human data. |
| Study type | 4 - Animal Study |
| Model system | Genetically heterogeneous mice |
| Journal | Aging Cell |
| Year | 2012 |
| Peer reviewed | Yes |
| Record last updated | 2026-08-22 |
| Source | DOI 10.1111/j.1474-9726.2012.00832.x · PMID 22587563 · Free full text (PMC3434687) |
Extracted findings
| Intervention | Rapamycin |
| Target | mTOR |
| Model | Genetically heterogeneous mice |
| Effect | Rapamycin slows multiple aspects of aging (heart, liver, tendon, activity), beyond just suppressing cancer |
| Dose | 4.7, 14, or 42 ppm rapamycin in food, administered from age 9 months. |
| Sample size | Genetically heterogeneous mice; young (4 month) and old (20-22 month) control groups, and old mice treated with rapamycin at 4.7, 14, or 42 ppm; N varies by outcome (e.g., 15-80 per group). |
| Effect size | Rapamycin significantly reduced incidences of liver degeneration (P=0.02), myocardial nuclear abnormalities (P=0.047), endometrial hyperplasia (P=0.05), and adrenal tumors (P=0.04); however, it increased cataract severity (P=0.014 males, P=0.001 females) and testicular degeneration (P<0.001). |
| Limitations | Histological evaluation of cataracts was limited to a small number of specimens; site-to-site variation was considerable for spontaneous activity; some observed trends did not reach statistical significance. |
In the Atlas
Related topics
More studies on this topic
- Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice (2016)
- Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster (2010)
- Late-life rapamycin treatment reverses age-related heart dysfunction (2013)
- Association of rapamycin treatment with the modulation of purine metabolism, reduced microglial inflammatory responses, improved mitochondrial energy metabolism, and alleviation of fatigue symptoms in ME/CFS subjects: pilot findings from phase-II observational study (2026)